OLIVOTTO, IACOPO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 29.551
EU - Europa 21.568
AS - Asia 18.853
SA - Sud America 3.108
Continente sconosciuto - Info sul continente non disponibili 656
AF - Africa 473
OC - Oceania 192
Totale 74.401
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 28.564
RU - Federazione Russa 6.326
IT - Italia 5.607
SG - Singapore 5.046
CN - Cina 4.999
PL - Polonia 3.751
BR - Brasile 2.426
HK - Hong Kong 2.234
VN - Vietnam 2.032
KR - Corea 1.584
IE - Irlanda 1.296
SE - Svezia 1.042
BD - Bangladesh 853
DE - Germania 739
FI - Finlandia 658
FR - Francia 643
CA - Canada 617
IN - India 544
GB - Regno Unito 530
ID - Indonesia 327
JP - Giappone 296
AR - Argentina 258
JO - Giordania 239
NL - Olanda 224
AU - Australia 187
MX - Messico 160
ES - Italia 158
TR - Turchia 155
UA - Ucraina 125
EC - Ecuador 110
IQ - Iraq 98
CH - Svizzera 90
CO - Colombia 86
ZA - Sudafrica 77
NG - Nigeria 76
MA - Marocco 63
PK - Pakistan 61
VE - Venezuela 60
AT - Austria 57
BE - Belgio 54
CI - Costa d'Avorio 52
PY - Paraguay 52
EG - Egitto 46
CL - Cile 41
PH - Filippine 41
AE - Emirati Arabi Uniti 34
GR - Grecia 34
MY - Malesia 34
PE - Perù 34
JM - Giamaica 31
KE - Kenya 31
UZ - Uzbekistan 31
BJ - Benin 29
DK - Danimarca 29
SA - Arabia Saudita 29
TN - Tunisia 29
CR - Costa Rica 28
RO - Romania 28
TT - Trinidad e Tobago 27
LT - Lituania 25
DO - Repubblica Dominicana 24
PT - Portogallo 24
HN - Honduras 23
TW - Taiwan 23
IR - Iran 21
NP - Nepal 21
UY - Uruguay 21
DZ - Algeria 19
BG - Bulgaria 18
CZ - Repubblica Ceca 18
IL - Israele 18
GT - Guatemala 17
NI - Nicaragua 17
KZ - Kazakistan 16
AZ - Azerbaigian 15
AL - Albania 14
RS - Serbia 14
TH - Thailandia 14
BO - Bolivia 13
HU - Ungheria 13
NO - Norvegia 12
PR - Porto Rico 12
OM - Oman 10
GH - Ghana 9
BY - Bielorussia 8
QA - Qatar 8
SC - Seychelles 8
SV - El Salvador 8
SY - Repubblica araba siriana 8
HR - Croazia 7
LK - Sri Lanka 7
PS - Palestinian Territory 7
BB - Barbados 6
CY - Cipro 6
KG - Kirghizistan 6
KW - Kuwait 6
LB - Libano 6
XK - ???statistics.table.value.countryCode.XK??? 6
AM - Armenia 5
MU - Mauritius 5
Totale 73.650
Salva come PNG Salva come JPEG
Città #
Santa Clara 5.221
Ashburn 3.872
Singapore 3.737
Warsaw 3.704
Hong Kong 1.948
Fairfield 1.601
Seoul 1.564
San Jose 1.520
Hefei 1.508
Dublin 1.286
Milan 941
Council Bluffs 799
Woodbridge 776
Seattle 751
Chandler 744
Beijing 742
Houston 667
Ho Chi Minh City 655
Cambridge 624
Los Angeles 605
Rome 578
New York 570
Wilmington 555
Florence 494
Lawrence 447
Altamura 437
Buffalo 432
Hanoi 427
Dallas 421
Helsinki 407
Moscow 376
Lauterbourg 371
The Dalles 313
Munich 299
Ann Arbor 275
Princeton 272
North Bergen 253
Boston 248
Jakarta 231
São Paulo 230
Tokyo 230
Mumbai 225
Phoenix 212
Naples 184
Toronto 173
Kent 172
Shanghai 162
Melbourne 153
Dong Ket 151
San Diego 142
Boardman 140
Frankfurt am Main 129
Chicago 126
Bologna 117
London 117
Lappeenranta 109
Turin 106
Montreal 105
Medford 104
Atlanta 102
Turku 102
Paris 101
Bengaluru 100
Orem 92
Da Nang 86
Figino 81
Haiphong 78
Palermo 78
Rio de Janeiro 77
Jacksonville 73
Abuja 66
Istanbul 66
Brooklyn 63
Guangzhou 63
Denver 61
Washington 58
Bern 56
Brasília 56
Redondo Beach 56
Bari 55
Nuremberg 54
Chennai 53
Columbus 53
Genoa 53
Abidjan 52
Bayreuth 52
Norwalk 51
Barcelona 50
Belo Horizonte 50
Clifton 47
Mexico City 47
Ottawa 46
Philadelphia 46
San Francisco 46
Shenzhen 46
Guayaquil 44
Johannesburg 44
Biên Hòa 42
Brussels 41
Catania 41
Totale 46.286
Salva come PNG Salva come JPEG
Nome #
Effects of myocardial fibrosis assessed by MRI on dynamic left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy: A retrospective database analysis 506
"Tuscany Registry for sAdden Cardiac DEath": metodo per la creazione di un registro multicentrico per la gestione di eventi di morte improvvisa in età giovanile 498
Atrial Remodeling in Hypertrophic Cardiomyopathy 413
Accade-MIA. Territorio, Università e Ospedale si incontrano. Il racconto di un’esperienza 411
Incidence and determinants of atrial fibrillation in patients with wild-type transthyretin cardiac amyloidosis 376
The familial hypertrophic cardiomyopathy-associated myosin mutation R403Q accelerates tension generation and relaxation of human cardiac myofibrils 365
Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC) 364
Pathogenesis of hypertrophic cardiomyopathy is mutation rather than disease specific: A comparison of the cardiac troponin T E163R and R92Q mouse models 356
Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations. 355
Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy 337
Regulation of intracellular Na+ in health and disease: pathophysiological mechanisms and implications for treatment 334
Validation of pixel-wise parametric mapping of myocardial blood flow with ¹³NH₃ PET in patients with hypertrophic cardiomyopathy. 323
Clinical Features and Outcome of Hypertrophic Cardiomyopathy Associated With Triple Sarcomere Protein Gene Mutations 317
Comparison of long-term outcome in anthracycline-related versus idiopathic dilated cardiomyopathy: a single centre experience 317
Relationship between atrial fibrillation and blunted hyperemic myocardial blood flow in patients with hypertrophic cardiomyopathy. 316
Microvascular dysfunction, myocardial ischemia, and progression to heart failure in patients with hypertrophic cardiomyopathy 306
Significance of sarcomere gene mutations analysis in the end-stage phase of hypertrophic cardiomyopathy 303
IN VIVO OBSERVATION OF RETINAL VASCULAR DEPOSITS USING ADAPTIVE OPTICS IMAGING IN FABRY DISEASE 302
Late sodium current inhibitors to treat exercise induced obstruction in hypertrophic cardiomyopathy: an in vitro study in human myocardium. 302
β Blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy 296
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial 295
Predicting Mortality Risk in Older Hospitalized Persons With COVID-19: A Comparison of the COVID-19 Mortality Risk Score with Frailty and Disability 292
Optimal timing of follow-up cardiac magnetic resonance in patients with uncomplicated acute myocarditis 291
Clinical profile and outcome of cardiac involvement in MELAS syndrome 291
Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy 283
Defining the diagnostic effectiveness of genes for inclusion in panels: the experience of two decades of genetic testing for hypertrophic cardiomyopathy at a single center 279
Position paper ANMCO: Cardiomiopatia ipertrofica: dalla diagnosi al trattamento 264
Prognostic role of stress echocardiography in hypertrophic cardiomyopathy: The International Stress Echo Registry 260
Impact of Pregnancy on the Natural History of Women with Hypertrophic Cardiomyopathy 258
Hemodynamic progression and outcome of asymptomatic aortic stenosis in primary care 256
Electrophysiological and Contractile Effects of Disopyramide in Patients With Obstructive Hypertrophic Cardiomyopathy: a Translational Study 253
Clinical Exome Sequencing Revealed a De Novo FLNC Mutation in a Child with Restrictive Cardiomyopathy 249
Dissecting functional impairment in hypertrophic cardiomyopathy by dynamic assessment of diastolic reserve and outflow obstruction: A combined cardiopulmonary-echocardiographic study 249
Myocardial bridging and sudden death in hypertrophic cardiomyopathy: Salome drops another veil 247
International external validation study of the 2014 European society of cardiology guidelines on sudden cardiac death prevention in hypertrophic cardiomyopathy (EVIDENCE-HCM) 246
Metabolomics Fingerprint Predicts Risk of Death in Dilated Cardiomyopathy and Heart Failure 241
Myocardial blood flow and left ventricular functional reserve in hypertrophic cardiomyopathy: a 13NH3 gated PET study 237
Participation in thrill-seeking activities by patients with hypertrophic cardiomyopathy: Individual preferences, adverse events and physician attitude 236
Can anthropology improve our care of inherited cardiac arrhythmias? A modest proposal 236
Long-Term Prevalence of Systolic Dysfunction in MYBPC3 Versus MYH7-Related Hypertrophic Cardiomyopathy 234
Clinical Course and Significance of Hypertrophic Cardiomyopathy Without Left Ventricular Hypertrophy 233
Echocardiography in patients with hypertrophic cardiomyopathy: Usefulness of old and new techniques in the diagnosis and pathophysiological assessment 232
Genotype and lifetime burden of disease in hypertrophic cardiomyopathy insights from the sarcomeric human cardiomyopathy registry (SHaRe) 231
Impact of demographic features, lifestyle, and comorbidities on the clinical expression of hypertrophic cardiomyopathy 228
Left Ventricular Apex Involvement in Hypertrophic Cardiomyopathy 228
Malattia di Anderson-Fabry 228
An Investigation of the Molecular Mechanism of Double cMyBP-C Mutation in a Patient with End-Stage Hypertrophic Cardiomyopathy 226
The electrocardiogram in the diagnosis and management of patients with dilated cardiomyopathy 225
Cardioprotective Strategy for Patients with Nonmetastatic Breast Cancer Who Are Receiving an Anthracycline-Based Chemotherapy: A Randomized Clinical Trial 225
Hypertrophic cardiomyopathy: prevalence of disease-specific red flags 224
Long-term Outcomes of Pediatric-Onset Hypertrophic Cardiomyopathy and Age-Specific Risk Factors for Lethal Arrhythmic Events 224
Clinical staging of Anderson-Fabry cardiomyopathy: An operative proposal 223
Prevalence and clinical significance of acquired left coronary artery fistulas after surgical myectomy in patients with hypertrophic cardiomyopathy 222
Development of a Novel Risk Prediction Model for Sudden Cardiac Death in Childhood Hypertrophic Cardiomyopathy (HCM Risk-Kids) 222
Molecular Modeling of Disease Causing Mutations in Domain C1 of cMyBP-C 221
Timing and significance of exercise-induced left ventricular outflow tract pressure gradients in hypertrophic cardiomyopathy 221
Sex-related differences in exercise performance and outcome of patients with hypertrophic cardiomyopathy 220
Stress echo 2030: The novel ABCDE-(FGLPR) protocol to define the future of imaging 220
Infection with SARS-CoV-2 Variants Is Associated with Different Long COVID Phenotypes 219
The Missense E258K-MyBP-C Mutation Increases the Energy Cost of Tension Generation in Both Ventricular and Atrial Tissue from HCM Patients 219
Beta-Blockers for Prevention of Exercise-induced Left Ventricular Outflow Obstruction in Patients with Hypertrophic Cardiomyopathy 219
Cardiac involvement in Churg Strauss syndrome: an update on cardiological manifestations 218
The Portuguese Registry of Hypertrophic Cardiomyopathy: Overall results 216
Care in Specialized Centers and Data Sharing Increase Agreement in Hypertrophic Cardiomyopathy Genetic Test Interpretation 215
Incremental prognostic value of multiparametric echocardiographic assessment for severe aortic stenosis 214
Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives 213
Life-Threatening Acute Pulmonary Thromboembolism Following Severe Carbon Monoxide Poisoning 213
Electrophysiological correlates of word recognition memory process in patients with ischemic left ventricular dysfunction 211
MR imaging in hypertrophic cardiomyopathy: From magnet to bedside 211
Clinical profile and outcome of cardiomyopathies in infants and children seen at a tertiary centre 210
Ranolazine prevents phenotype development in a mouse model of hypertrophic cardiomyopathy 210
Intraoperative diagnosis of Anderson-Fabry disease in patients with obstructive hypertrophic cardiomyopathy undergoing surgical myectomy 209
[Therapeutic approaches in hypertrophic cardiomyopathy: from symptom relief to precision therapy] 207
Cardiac Resynchronization Therapy for End-Stage Hypertrophic Cardiomyopathy: The Need for Disease-Specific Criteria 207
Stress echo 2020: The international stress echo study in ischemic and non-ischemic heart disease 207
Advances in Stem Cell Modeling of Dystrophin-Associated Disease: Implications for the Wider World of Dilated Cardiomyopathy 204
Changes in the perceived epidemiology of amyloidosis: 20 year-experience from a Tertiary Referral Centre in Tuscany 204
Arrhythmic risk stratification in patients with left ventricular ring-like scar 203
Impact of Genotype on the Occurrence of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy. 203
Reversible dilated cardiomyopathy: into the thaumaturgy of the heart - Part 2 203
The coronary circulation and blood flow in left ventricular hypertrophy 203
Determinants of health status in older patients with transthyretin cardiac amyloidosis: a prospective cohort study 202
Impact of cardiovascular involvement on the clinical course of paediatric mitochondrial disorders 202
Update sulla gestione del paziente con cardiomiopatia ipertrofica alla luce delle nuove linee guida nord-americane 201
Quantitative approaches to variant classification increase the yield and precision of genetic testing in Mendelian diseases: The case of hypertrophic cardiomyopathy 200
An expert consensus document on the management of cardiovascular manifestations of Fabry disease 200
[Molecular targets and novel pharmacological options to prevent myocardial hypertrophic remodeling] 200
Slower Calcium Handling Balances Faster Cross-Bridge Cycling in Human MYBPC3 HCM 196
Timing of invasive septal reduction therapies and outcome of patients with obstructive hypertrophic cardiomyopathy 196
Contemporary genetic testing in inherited cardiac disease: Tools, ethical issues, and clinical applications 196
Late Sodium Current Inhibition Reverses Electro-Mechanical Dysfunction in Human Hypertrophic Cardiomyopathy 196
Usefulness of Electrocardiographic Patterns at Presentation to Predict Long-term Risk of Cardiac Death in Patients With Hypertrophic Cardiomyopathy 196
Come nasce Accade-MIA: accorciamo le distanze? Esperienze professionali diverse si incontrano 195
Contemporary Insights Into the Genetics of Hypertrophic Cardiomyopathy: Toward a New Era in Clinical Testing? 195
Electromechanical dissociation of left atrium in patients with Cardiac Amyloidosis by Magnetic Resonance: Prognostic and clinical correlates 195
Cardiac involvement in eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome): Prospective evaluation at a tertiary referral centre 195
BPS2025 - Long-term effect of Mavacamten impact force and sarcomere density in a MYBPC3 iPSC-cardiomyocyte model of hypertrophic cardiomyopathy 194
Clinical Spectrum, Therapeutic Options, and Outcome of Advanced Heart Failure in Hypertrophic Cardiomyopathy 193
Doctor-patient care relationship in genetic cardiomyopathies: An exploratory study on clinical consultations 192
Multidimensional structure-function relationships in human β-cardiac myosin from population-scale genetic variation 192
Totale 24.921
Salva come PNG Salva come JPEG
Categoria #
all - tutte 209.516
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 209.516
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.955 0 0 188 83 46 119 91 130 252 135 319 592
2022/20235.281 456 1.217 302 176 288 903 736 286 571 54 173 119
2023/20242.747 111 224 369 140 164 417 156 543 89 268 146 120
2024/202518.401 630 1.837 1.020 2.560 4.383 2.318 569 1.009 1.101 639 1.047 1.288
2025/202631.449 2.685 3.877 3.521 3.637 2.769 1.052 2.923 1.556 2.084 1.928 1.996 3.421
2026/20274.609 1.735 1.521 1.353 0 0 0 0 0 0 0 0 0
Totale 74.401